Stocksigma LogoStocksigma Logo

Tavexia Lifecare Q2 Results, Acquisition Funding, and RTA Change

Tavexia Lifecare's Board approved in-principle fundraising of up to ₹68.00 crore across tranches to finance acquiring a 60% stake in Meyonex

Tavexia Lifecare Q2 Results, Acquisition Funding, and RTA Change

Sattva Sukun Lifecare Ltd · Others (Uncategorized) · 05 Nov 2026, 3:11 am

Tavexia Lifecare Q2 Results, Acquisition Funding, and RTA Change Tavexia Lifecare's Board approved in-principle fundraising of up to ₹68.00 crore across tranches to finance acquiring a 60% stake in Meyonex Pharmaceuticals. For Q2 ended 30th Sep'26, consolidated revenue fell 70.1% YoY to ₹503.94 lakh versus ₹1,684.33 lakh, posting a net loss of ₹40.12 lakh against a profit of ₹78.21 lakh in Q2'25. Standalone Q2 revenue dropped 91.9% YoY to ₹15.80 lakh, with a net loss of ₹51.40 lakh. Separately, the company approved transitioning its RTA from Niche Technologies to Skyline Financial Services.

Original exchange filing (PDF)

More announcements from Sattva Sukun Lifecare Ltd

All Sattva Sukun Lifecare Ltd announcements